AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 55,000
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
30% more call options, than puts
Call options by funds: $2.25B | Put options by funds: $1.72B
16% more repeat investments, than reductions
Existing positions increased: 1,663 | Existing positions reduced: 1,432
1.58% more ownership
Funds ownership: 71.14% [Q1] → 72.72% (+1.58%) [Q2]
6% more first-time investments, than exits
New positions opened: 171 | Existing positions closed: 162
2% less funds holding
Funds holding: 3,757 [Q1] → 3,675 (-82) [Q2]
10% less capital invested
Capital invested by funds: $264B [Q1] → $237B (-$26.6B) [Q2]
38% less funds holding in top 10
Funds holding in top 10: 243 [Q1] → 150 (-93) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$227
9%
upside
Avg. target
$237
14%
upside
High target
$255
23%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Amsellem | 11%upside $231 | Overweight Assumed | 12 Aug 2025 |
Guggenheim Vamil Divan | 9%upside $227 | Buy Maintained | 1 Aug 2025 |
Morgan Stanley Terence Flynn | 23%upside $255 | Overweight Maintained | 1 Aug 2025 |
Raymond James Gary Nachman | 14%upside $236 | Outperform Maintained | 1 Aug 2025 |
Financial journalist opinion
Based on 72 articles about ABBV published over the past 30 days
Positive
Seeking Alpha
21 hours ago
AbbVie Is A Top Biotech Pick
Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential and U.S. manufacturing plans are likely to help mitigate tariff headwinds successfully. EPS guidance for the full year was raised and consensus estimates also show that the outlook for AbbVie is a strong one.
Positive
Reuters
22 hours ago
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion
AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.
Neutral
PRNewsWire
22 hours ago
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser.
Positive
Seeking Alpha
1 day ago
Best Dividend Kings: August 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued with expected long-term annualized returns of at least 10%, based on Dividend Yield Theory analysis. Recent dividend increases have modestly boosted the group's 2025 dividend growth rate, though it still trails last year's pace.
Positive
The Motley Fool
1 day ago
3 Top Stocks to Build Your Portfolio Around
Building a portfolio capable of earning strong returns over long periods is not easy, but there are some basic principles we can try to follow to simplify the task. One is to start with companies that are well established in their fields and have robust operations.
Negative
Seeking Alpha
2 days ago
AbbVie Investors Beware: Strong Growth Potential, Rising Risks
AbbVie has delivered strong total returns and dividend growth over time. Additionally, it enjoys strong growth prospects. However, it also faces significant uncertainty and risks.
Positive
The Motley Fool
3 days ago
3 Unstoppable Dividend Stocks to Buy Right Now
How does getting paid to own a stock sound to you? That's exactly what dividends do.
Positive
Zacks Investment Research
3 days ago
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
Positive
Zacks Investment Research
3 days ago
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
Neutral
PRNewsWire
4 days ago
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 201 Key secondary endpoints, including improvements in eyebrows and eyelashes, as well as the percentage of subjects with 90% or more scalp coverage (SALT ≤ 10) and complete scalp hair coverage (SALT=0) at week 24, were also met 1 The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study1 These results are consistent with the topline results from the first parallel replicate study (Study 2) of the Phase 3 UP-AA clinical program NORTH CHICAGO, Ill. , Aug. 21, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage).1 In Study 1, both doses of upadacitinib achieved the primary endpoint, with 45.2% and 55.0% of patients treated with upadacitinib 15 mg and 30 mg, respectively, reaching 80% or more scalp hair coverage (SALT score ≤ 20) at week 24, compared to 1.5% of patients receiving placebo (p
Charts implemented using Lightweight Charts™